Navigation Links
Optherion Announces Issuance of Canadian Patents Covering Age-Related Macular Degeneration Diagnostics and Treatments
Date:4/30/2009

Issuance of Canadian Patents 2,363,503 and 2,407,715 Strengthens Intellectual Property Position of Optherion's Novel Diagnostics for Age-Related Macular Degeneration

NEW HAVEN, Conn., April 30 /PRNewswire/ -- Optherion, Inc., a company developing novel molecular diagnostics and treatments for dry and wet Age-related Macular Degeneration (AMD) and other chronic diseases involving the alternative complement system, announced today that the Canadian Patent Office has granted patents 2,363,503 and 2,407,715.

The claims of the issued patents provide secure protection for diagnostic tests for determining the predisposition to AMD by screening for genetic modifications in several genes including complement factor H (CFH), complement factor B (CFB), complement factor 2 (C2) and complement factor 3 (C3) amongst others. Optherion has an exclusive worldwide license to these Canadian patent rights, the corresponding PCT patents and applications from the University of Iowa Research Foundation.

Colin J. Foster, Optherion's President and CEO, said: "The issuance of the Canadian patents is an important milestone in the development of our diagnostics business. With these and other patents pending, licensed from almost a dozen universities, we are well positioned to exclusively offer a range of predictive and prognostic diagnostic tests to healthcare professionals treating patients with AMD and other diseases of the alternative complement system. As we advance to commercialization, we will continue to develop and protect our intellectual property covering our novel products."

Optherion is developing a genetic test for AMD and is pursuing commercialization discussions with several providers within North American and international markets.

About Optherion:

Optherion, Inc. is a private, innovative biotechnology company that is developing protein therapeutics and molecular diagnostics for the management of dry and wet Age-related Macular Degeneration (AMD) and other chronic diseases involving the alternative complement system. Optherion's proprietary technologies are based on landmark scientific discoveries linking certain genes to AMD.


'/>"/>
SOURCE Optherion, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
5. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
6. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
7. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
8. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
9. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
10. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
11. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... 2017  Novartis announced today that the US ... company,s Biologics License Application (BLA) filing and granted ... antigen receptor T cell (CAR-T) therapy, in relapsed ... with B-cell acute lymphoblastic leukemia (ALL). This is ... CAR-T. The priority review designation is expected to ...
(Date:3/29/2017)... , March 29, 2017  The Global Health ... public-private partnership formed to battle infectious diseases around ... US$23 million* that could help deliver a range ... debilitating conditions. This latest round ... 3 clinical trial testing a pediatric formulation of ...
(Date:3/29/2017)... FREMONT, Calif. , March 29, 2017 /PRNewswire/ ... vision for patients as the highest standard in ... Today, Krypton Vision introduces its objective Wavefront-driven refraction ... conventional, subjective approach. This enables an unprecedented level ... optics - exceptional vision relegated to Topgun Navy ...
Breaking Medicine Technology:
(Date:3/30/2017)... ... March 30, 2017 , ... Watch the video ... Month, representatives from Organic Consumers Association, National Health Freedom Action, March Against Monsanto, ... Voice for Choice, Moms Across America, Freedom and Ethics Alliance and the Vaccine ...
(Date:3/30/2017)... (PRWEB) , ... March 30, 2017 , ... ... host the live audio conference “ Preventing Hospital Readmissions Through Discharge Planning ” ... 2017 at 1:00 pm ET. This conference discusses strategies to prevent readmissions in ...
(Date:3/29/2017)... WI (PRWEB) , ... March 29, 2017 , ... ARI ... its exclusive provider of co-op eligible dealer websites for its network of more than ... of professional landscaping and agricultural equipment including rotary and flail mowers and cutters, rear ...
(Date:3/29/2017)... ... March 29, 2017 , ... Full Contact K9, an ... Pet Protect Law that assists dog owners in creating legally-enforceable pet trusts ... in taking the natural next step to protect their new companion. Says Evan Dunbar, ...
(Date:3/29/2017)... ... ... Youth Futures International (YFI) premiered its Serve, Learn, & Empower program in ... who have participated in the program every summer. The 2017 Serve, Learn, & ... enrollment. Visit http://www.ghana.yfiexperience.org to learn more. , “I have sent my ...
Breaking Medicine News(10 mins):